JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Validation of the Lung-Mol Graded Prognostic Assessment (GPA) System for the Prognosis of Patients Receiving Radiotherapy for Brain Metastasis From Non-small Cell Lung Cancer

  • 0Department of Radiation Oncology and Image-Applied Therapy, Kyoto University Graduate School of Medicine, Kyoto, JPN.
Cureus +

|

May 6, 2024

|

May 6, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

The Lung-mol graded prognostic assessment (GPA) system effectively predicts survival for non-small cell lung cancer patients with brain metastases receiving radiotherapy. Its validity is confirmed for initial treatment and shows promise for subsequent therapy in adenocarcinoma cases.

Area Of Science

  • Oncology
  • Radiotherapy
  • Prognostic Assessment

Background

  • Brain metastases (BM) from non-small cell lung cancer (NSCLC) require accurate prognostic tools.
  • The Lung-mol graded prognostic assessment (GPA) system stratifies NSCLC patients with BM based on histology.
  • Validation of prognostic systems is crucial for clinical decision-making.

Purpose Of The Study

  • To validate the Lung-mol GPA system in a local cohort of NSCLC patients treated with radiotherapy for BM.
  • To assess the system's predictive accuracy for both adenocarcinoma and non-adenocarcinoma subtypes.
  • To evaluate the Lung-mol GPA system's performance during both first and second courses of radiotherapy.

Main Methods

  • A cohort of 339 NSCLC patients receiving initial radiotherapy for BM was analyzed.
  • Data including Karnofsky performance status, extracranial metastases, and histology were collected.
  • The prognostic factors and overall system validity were examined for predicting survival.

Main Results

  • Lung-mol GPA factors were significantly associated with survival, with minor exceptions.
  • C-indices ranged from 0.62 to 0.74, indicating moderate discrimination ability.
  • Survival predictions aligned well with actual outcomes, particularly for the first radiotherapy course.

Conclusions

  • The Lung-mol GPA system is validated for estimating median survival in NSCLC patients with BM undergoing initial radiotherapy.
  • The system demonstrates potential applicability for adenocarcinoma patients during a second course of radiotherapy.
  • Prognostic assessment aids in tailoring treatment strategies for NSCLC with brain metastases.

Keywords: